FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: February 28, 2011
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Kiss Szilard
2. Date of Event Requiring Statement (Month/Day/Year)
06/10/2024		 3. Issuer Name and Ticker or Trading Symbol
Adverum Biotechnologies, Inc. [ADVM]
(Last)
(First)
(Middle)
C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
5. If Amendment, Date Original Filed (Month/Day/Year)
(Street)

REDWOOD CITY, CA 94063		 6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4) 		2. Amount of Securities Beneficially Owned
(Instr. 4) 		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) 		4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4) 		2. Date Exercisable and Expiration Date
(Month/Day/Year) 		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) 		4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) 		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)   (1) 11/01/2026 Common Stock 1,250 $ 30.5 D  
Stock Option (Right to Buy)   (1) 09/12/2028 Common Stock 2,000 $ 61.5 D  
Stock Option (Right to Buy)   (1) 03/24/2029 Common Stock 8,000 $ 54.1 D  
Stock Option (Right to Buy)   (1) 03/29/2031 Common Stock 4,500 $ 94.5 D  
Stock Option (Right to Buy)   (2) 08/15/2032 Common Stock 2,500 $ 14 D  
Stock Option (Right to Buy)   (3) 05/24/2033 Common Stock 2,500 $ 9.6 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Kiss Szilard
C/O ADVERUM BIOTECHNOLOGIES, INC.
100 CARDINAL WAY
REDWOOD CITY, CA 94063		   X      

Signatures

/s/ John Rakow, Attorney-in-Fact 06/20/2024
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Stock option is fully vested and exercisable.
(2) The shares subject to the option vest in equal monthly installments over two years, such that all of the shares subject to the option shall become vested and exercisable as of August 16, 2024, subject to the Reporting Person's continued service with the Issuer on each such vesting date.
(3) 50% of the shares subject to the option vested on March 25, 2024, and the remainder of the shares subject to the option vest in equal monthly installments thereafter through March 25, 2025, subject to the Reporting Person's continued service with the Issuer on each such vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.